HER2-Positive Hub Overview
also known as HER2+ Breast Cancer
This section is for HER2-positive breast-cancer topics that need their own treatment and resistance context.
It focuses on regimen-specific summaries, progression questions, biomarker interpretation, and adjunctive considerations that are specific to HER2-positive disease rather than breast cancer in general.
Key pages in this section so far
Metabolic Pathways in HER2+ Breast Cancer — 18th September Update: This hub is coming very soon.
HER2CLIMB — regimen-specific guide to tucatinib, trastuzumab, and capecitabine, including resistance, testing, and interaction questions
Enhertu, Senescence, and the Senolytic Second Strike — explains how trastuzumab deruxtecan may leave behind senescent or dormant cells and why post-cycle timing is being discussed
Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin? — quick practical answer on the HER2+/ERα+ caution, with the main takeaway upfront
FOX Family in ER+/HER2+ Metastatic Breast Cancer — maps FOXA1 and FOXM1 biology, resistance routes, and why these signals matter in bone-metastatic dual-positive disease
HER2+ Breast Cancer – Integrative Protocols — a private group that gathers protocol ideas, research themes, and support notes specific to HER2-positive care
Support Threads & Docs — direct links to group discussions and shared documents relevant to HER2-positive patients